Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Wells Fargo Initiates Coverage On NuVasive with Overweight Rating, Announces Price Target of $58
Wells Fargo analyst Larry Biegelsen initiates coverage on NuVasive (NASDAQ:NUVA) with a Overweight rating and announces Price Target of $58.
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell
• Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
Where NuVasive Stands With Analysts
NuVasive (NASDAQ:NUVA) has observed the following analyst ratings within the last quarter:
Morgan Stanley Maintains Equal-Weight on NuVasive, Lowers Price Target to $60
Morgan Stanley maintains NuVasive (NASDAQ:NUVA) with a Equal-Weight and lowers the price target from $62 to $60.
Why Did BofA Securities Give Globus Medical A Double Upgrade?
Enabling tech is likely to continue driving Globus Medical Inc’s (NYSE: GMED) market share gains in 2022, according to BofA Securities.
RBC Capital Initiates Coverage On NuVasive with Outperform Rating, Announces Price Target of $60
RBC Capital analyst Shagun Singh initiates coverage on NuVasive (NASDAQ:NUVA) with a Outperform rating and announces Price Target of $60.